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Translational medicine is an emerging medical practice that 
involves multidisciplinary collaborations to bridge between 
basic sciences and clinical use, aiming at enhancing patient 
care and preventive measures. As it suggests for most, basic 
scientists in particular, the term “translational medicine” 
may literally imply a uni-directional endeavor to use data or 
findings in basic research for development of novel thera-
pies or medical procedures, and then test them in humans. 
This is not always the case, because what is found in labor-
atories does not fully mean what should happen in a re-
al-world human body. More efforts need to be focused on 
feedback understandings of how humans react to the treat-
ment. In fact, the one-way concept no longer suffices, and a 
two-way feature of translational medicine has been pro-
posed elsewhere [1]: from bench to bedside and from bed-
side to bench.  
Although starting late, translational medicine as an in-
ter-disciplinary science is developing rapidly and widely in 
China. Sustainability of such development entails close col-
laboration between persons on laboratory benches and those 
at the bedside. Unfortunately, the paradigm between basic 
and clinical science has often put these two disciplines at 
odds with each other [2], and communications between basic 
and clinical scientists is rare and sporadic [3]. The ultimate 
goal of this science behooves us to have a better look at what 
translational medicine means to Chinese clinicians.  
For the part of Chinese clinicians, translational medicine 
may be interpreted in several directions (Figure 1). 
 
Figure 1  On the part of Chinese clinicians, the routes of translation 
should ideally be set as (i) from bench to bedside; (ii) from empirical to  
evidence based, and (iii) from bedside to bench then back to bedside. 
1  From bench to bedside 
“From bench to bedside” represents the traditional one-way 
modality of translational medicine, in which, clinicians are 
recipients of overwhelming data surging out of the basic 
science community. Since China is a developing country 
with a large population of patients but very limited financial 
resources, our clinicians need to translate laboratory find-
ings into simpler, cheaper and effective products or 
measures with less adverse effects for purposes of clinical 
diagnosis and management. 
This rationale can be well illustrated with our previous 
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study on chronic obstructive pulmonary disease (COPD). 
COPD, one of the most common chronic respiratory dis-
eases in China, is a pathological process involving oxidative 
stress that contributes substantially to inflammation in the 
airway [4–7]. In vitro study has shown that thiol compounds 
(e.g., N-acetyl-carbocisteine) are selective scavenger of 
reactive intermediates [8]. Mo et al. [9,10] also demon-
strated that thiol compounds exhibit strong antioxidative 
properties by inhibiting activation of transcription factor 
(e.g., NF-kB) and cytokine release (IL-6, IL-8), inhibiting 
lipid peroxidase (LPO) and enhancing antioxidant levels 
(serum glutathione) in smoking rat COPD models. 
Based on these preliminary results, along with much 
more from certain suboptimally-designed clinical trials, we 
conducted a randomized, double-blind, parallel-group, and 
placebo-controlled multicenter study (Preventive Effect on 
Acute exacerbation of COPD with CarbocistEine (PEACE 
study)). Compared with placebo, the use of carbocisteine for 
one year was associated with a 24.5% reduction in frequen-
cy of COPD exacerbation (1.35 vs. 1.01 episodes per pa-
tient-year), improved quality of life as measured by St 
George’s Respiratory Questionnaire (SGRQ) and no appar-
ent adverse effects, although the lung function did not show 
any significant change from baseline in either of the two 
arms [11]. Importantly, carbocisteine showed satisfactory 
efficacy in reducing exacerbation rate of COPD comparable 
with inhaled corticosteroids plus long-acting -agonists 
(ICS+LABA) or Tiotropine, and was more affordable (only 
one-sixth of the medical costs with standard treatments) and 
more simple to be used (oral administration) [11]. This 
study was rated later as “paper of the year 2008” by Lan-
cet’s Editorial Board [12]. In an accompanying editorial, 
Albert and Calverley commented that the PEACE study has 
“offered a cost-effective and well-tolerated way of lessening 
the burden of exacerbations for the growing number of pa-
tients in developing countries affected by this chronic and 
debilitating condition” [13]. 
2  From empirical to evidence-based practicing 
Traditional Chinese medicine (TCM) is a broad set of heal-
ing theories and practices whose practitioners trace its ori-
gins to ancient Chinese texts dating back over 2000 years. 
TCM is currently not only widely practiced among Chinese, 
but also increasingly popular among non-Chinese in many 
countries. The use of treatment methods and herbal formu-
las in TCM remains largely empirical, and therefore the 
management and outcomes may vary from case to case. In 
an era of modern biomedicine, TCM has been constantly 
criticized for settling for a low standard of evidence. Some 
professionals stressed the dire need for evidenced-based 
practicing of TCM, in order to enhance patient care and 
promote the scientific reputation of TCM worldwide [14]. 
Moving TCM from empirical to evidence-based practicing 
can be another important interpretation of translational 
medicine among Chinese clinicians.  
In ancient China, management of diseases depended on the 
doctors’ experiences. For example, patients with influenza 
were commonly treated with decoctions of certain herbal 
formula, such as weeping forsythia, heartleaf houttuynia 
herb and honeysuckle flower. During the 2009/2010 out-
break of swine flu, a randomized, double-blind clinical trial 
of those natural herbal medicine (in the form of a commer-
cially available product, Lianhua Qingwen capsule (LHC)) 
was conducted in 244 patients [15], with oseltamivir as the 
active control. Compared with the control, LHC yielded 
similar therapeutic efficacy in ameliorating illness and viral 
shedding duration, suggesting that LHC might be used as an 
alternative therapeutic agent for H1N1 infection.  
Chinese medicine is a great treasure to China and the 
world. In essence, the empirically-practicing aspect of TCM 
may reflect a clinical result-based pathway. In this process, 
what works consistently is kept, what does not is discarded, 
and thereby the entire system has been refined over centu-
ries. Yet in the old times without pooled data from large-      
scale clinical observational studies, such a bedside-to-      
bedside refinement seems not efficient and convincing. 
Nowadays more and more well-designed clinical studies are 
on-going for evaluating the clinical efficacy of certain Chi-
nese herbs, although they have been in widespread use 
among Chinese. We believe that evidence-based TCM in 
the future should owe much to our new vision of transla-
tional medicine today, and would contribute to better treat-
ment for patients, a highly respected position of its own 
alongside biomedicine, or a new integrated medicine for 
best practices.  
3  From bedside to bench to bedside 
From a clinical perspective, prioritized topics for laboratory 
research should be those originating from clinical practices. 
Laboratory research should be focused on hot topics with 
greatest clinical relevance, and the subsequent findings can 
then be used immediately to make a difference in clinical 
practices. This strategy has shown benefits in more than one 
story.  
3.1  Use of artemisinin in management of malaria 
Earliest description of anti-malarial effects of Artemisia 
annua in China was written by Ge Hong (284–364 AD, 
Eastern Jin Dynasty) in a medical text called “A Handbook 
of Prescriptions for Emergency Treatments” (circa 340 AD). 
In China, a crude extract of Artemisia annua has been used 
for over 2000 years. In 1971, a collaborating team led by Tu 
YouYou rediscovered this anti-malarial activity; later, a 
purer crystalline extract named artemisinin was found, 
which showed strong actions against plasmodium, in partic-
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ular, the plasmodium falciparum [16]. Further efforts by Tu 
et al. resulted in development of a novel compound (re-
duced type of artemisinin), which was 10 times more pow-
erful than artimisinin [17]. Ever since, the compound has 
been modified and used worldwide. In a report of WHO 
Technical Consultation on Antimalarial Combination Ther-
apy held in Geneva, Switzerland on 4–5 April, 2001, the 
advantages of artemisinin-based combination chemotherapy 
was well-documented [18]. The merits of artemisinin were 
also demonstrated by a medical team in a one-year fast 
elimination of malaria by source eradication project on 
Moheli Island of Comoros [19]. Owing to her great contri-
bution in combating malaria, Prof. Tu YouYou was con-
ferred the Lasker Award on 23 September, 2011. 
3.2  Use of arsenic in management of leukemia 
Although a notorious poison, arsenic is also one of the old-
est drugs in both western medicine and traditional Chinese 
medicine, since it was mentioned by Hippocrates (462–370 
BC) for treatment of skin ulcer and by the Chinese Yellow 
Emperor’s Neijing (circa 263 BC) for treatment of malar-
ia-associated periodic fever. In the late 18th and early 19th 
centuries, arsenic, in the form of Fowler’s Solution (potas-
sium bicarbonate-based solution of arsenic), was introduced 
in clinics to treat periodic fever, chronic myelogenous leu-
kemia and many other diseases. In march 1971, pharmacists 
at the First Affiliated Hospital or Harbin Medical University 
developed a product called “Ai-ling No. 1” (also 713) based 
on a widespread empirical remedy, which contained 1 mg 
arsenic trioxide and 0.01 mg mL1 mercury chloride. The 
solution was used to treat patients with acute myeloid leu-
kemia. Surprisingly, the remission rate was 86.3% (26.27% 
with complete remission) after a 4-week intravenous ad-
ministration [20]. Being inspired by this clinical experience, 
Wang Z Y and Chen Z had further focused on the mecha-
nism of arsenic trioxide in the management of acute pro-
myelocytic leukemia (AML-M3) where there was an ab-
normal fusion gene (promyelocytic leukemia/retinoic acid 
receptor alpha fusion gene, or PML-RAR alpha fusion gene) 
arising from translocation between chromosomes 15 and 17. 
As2O3 inactivated the small ubiquitin-related modifier pro-
tein which was located on the PML-RAR alpha fusion gene. 
In combination with the RAR agonist all-trans retinoic acid, 
As2O3 was used in majority of patients with acute promye-
locytic leukemia, yielding a 5-year survival of >90% [21].  
This wonderful translation between bedside and bench 
has changed acute promyelocytic leukemia from highly 
fatal to highly curable [22]. 
3.3  Artificial infection with malaria parasites linked to 
anti-lung cancer therapy 
In collaborating with epidemiologists and using the WHO 
cancer mortality database, Chen et al. carried out a longitu-
dinal analysis looking at the incidence of malaria and the 
mortality of lung cancer in 29 countries from 1990 to 2006. 
In inverse growth and decline relationship between lung 
cancer mortality and malaria was found overall and in sore 
individual countries (such as Russia, Thailand, Guatemala 
and Tajikistan), as indicated by decreasing lung cancer rates 
in conjunction with increasing malaria incidence, and vice 
visa [23]. 
With this relationship in mind, we had conducted a series 
of studies to find out if malaria parasite infection is thera-
peutic for lung cancer by using both subcutaneously and 
intravenously implanted murine Lewis lung cancer (LLC) 
model. It was found that malaria infection inhibited LLC 
growth and metastasis and prolonged the survival of tu-
mor-bearing mice by inducing both a potent anti-tumor in-
nate immune response, including the secretion of IFN-      
gamma and TNF-alpha and the activation of NK cells. 
Meanwhile, tumor-bearing mice infected with the parasite 
developed long-lasting and effective tumor specific immunity. 
Furthermore, malaria parasite infection enhanced the im-
mune response of lung cancer DNA vaccine (pcDNA 
3-hMUC1) and the combination produced a synergistic an-
titumor effect. These data suggested that the malaria para-
site may provide a novel strategy or therapeutic vaccine 
vector for anti-lung cancer immune-based therapy [23]. 
4  Conclusion 
Translational medicine targets at bridging between basic 
science and clinical practice. Understanding what it means 
may enable the Chinese clinicians to play an active role in 
this field. As clinicians, we need to be keen in tackling bed-
side problems on the bench, but never to be lost in the la-
boratory. A reasonable interpretation of translational medi-
cine will provide us assistance in diagnosis and manage-
ment of human diseases.  
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